Skip to main content
Erschienen in: Medical Oncology 12/2014

01.12.2014 | Original Paper

MicroRNA-146a rs2910164 polymorphism and the risk of diffuse large B cell lymphoma in the Chinese Han population

verfasst von: Haifeng Zhuang, Jianping Shen, Zhiyin Zheng, Xiusu Luo, Ruilan Gao, Xiaofen Zhuang

Erschienen in: Medical Oncology | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to determine the association of the microRNA-146a (miR-146a) polymorphism with the risk of diffuse large B cell lymphoma (DLBCL). The genotyping of miR-146a rs2910164 polymorphism was detected by polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP). The results showed that CC genotype and C alleles distribution in the DLBCL patient was significantly higher than that of the controls (p = 0.01 and p = 0.01, respectively). No significant differences were found between the two subgroups when stratified by clinical characteristics including sexual, age at admission, performance status, pathological type, Ann Arbor stage, LDH and β2-MG value. The miR-146a expression was detected by the Taqman real-time PCR. The result showed that the miR-146a expression was notably upregulated in DLBCL patients when compared with controls (p = 0.02). In addition, the miR-146a expression of CC genotypes subgroup was drastically downregulated than that of GC/GG genotype subgroup in DLBCL patients (p = 0.0003), suggesting that this polymorphism can functionally affect the expression of miR-146a. In conclusion, it was shown that the miR-146a rs2910164 polymorphism is associated with the risk of DLBCL in the Chinese Han population.
Literatur
1.
Zurück zum Zitat Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2006;403(6769):503–11.CrossRef Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2006;403(6769):503–11.CrossRef
2.
Zurück zum Zitat Troppan K, Wenzl K, Deutsch A, Ling H, Neumeister P, Pichler M. MicroRNAs in diffuse large B-cell lymphoma: implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Res. 2014;34(2):557–64.PubMed Troppan K, Wenzl K, Deutsch A, Ling H, Neumeister P, Pichler M. MicroRNAs in diffuse large B-cell lymphoma: implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Res. 2014;34(2):557–64.PubMed
3.
Zurück zum Zitat Caramuta S, Lee L, Ozata DM, Akçakaya P, Georgii-Hemming P, Xie H, et al. Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL). Blood Cancer J. 2013;3:e152.PubMedCentralPubMedCrossRef Caramuta S, Lee L, Ozata DM, Akçakaya P, Georgii-Hemming P, Xie H, et al. Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL). Blood Cancer J. 2013;3:e152.PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Qiu LX, He J, Wang MY, Zhang RX, Shi TY, Zhu ML, et al. The association between common genetic variant of microRNA-146a and cancer susceptibility. Cytokine. 2011;56(3):695–8.PubMedCrossRef Qiu LX, He J, Wang MY, Zhang RX, Shi TY, Zhu ML, et al. The association between common genetic variant of microRNA-146a and cancer susceptibility. Cytokine. 2011;56(3):695–8.PubMedCrossRef
5.
Zurück zum Zitat Jeon HS, Lee YH, Lee SY, Jang JA, Choi YY, Yoo SS, et al. A common polymorphism in pre-microRNA-146a is associated with lung cancer risk in a Korean population. Gene. 2014;534(1):66–71.PubMedCrossRef Jeon HS, Lee YH, Lee SY, Jang JA, Choi YY, Yoo SS, et al. A common polymorphism in pre-microRNA-146a is associated with lung cancer risk in a Korean population. Gene. 2014;534(1):66–71.PubMedCrossRef
6.
Zurück zum Zitat Xu T, Zhu Y, Wei QK, Yuan Y, Zhou F, Ge YY, et al. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis. 2008;29:2126–31.PubMedCrossRef Xu T, Zhu Y, Wei QK, Yuan Y, Zhou F, Ge YY, et al. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis. 2008;29:2126–31.PubMedCrossRef
7.
Zurück zum Zitat Jazdzewski K, Liyanarachchi S, Swierniak M, Pachucki J, Ringel MD, Jarzab B, et al. Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc Natl Acad Sci USA. 2009;106:1502–5.PubMedCentralPubMedCrossRef Jazdzewski K, Liyanarachchi S, Swierniak M, Pachucki J, Ringel MD, Jarzab B, et al. Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc Natl Acad Sci USA. 2009;106:1502–5.PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, Welch DR. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res. 2009;69:1279–83.PubMedCentralPubMedCrossRef Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, Welch DR. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res. 2009;69:1279–83.PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci USA. 2008;105:7269–74.PubMedCentralPubMedCrossRef Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci USA. 2008;105:7269–74.PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Loktionov A. Common gene polymorphisms, cancer progression and prognosis. Cancer Lett. 2004;208(1):1–33.PubMedCrossRef Loktionov A. Common gene polymorphisms, cancer progression and prognosis. Cancer Lett. 2004;208(1):1–33.PubMedCrossRef
11.
Zurück zum Zitat Akkız H, Bayram S, Bekar A, Akgöllü E, Usküdar O, Sandıkçı M. No association of pre-microRNA-146a rs2910164 polymorphism and risk of hepatocellular carcinomadevelopment in Turkish population: a case-control study. Gene. 2011;486(1–2):104–9.PubMedCrossRef Akkız H, Bayram S, Bekar A, Akgöllü E, Usküdar O, Sandıkçı M. No association of pre-microRNA-146a rs2910164 polymorphism and risk of hepatocellular carcinomadevelopment in Turkish population: a case-control study. Gene. 2011;486(1–2):104–9.PubMedCrossRef
12.
Zurück zum Zitat Tomonaga M. Outline and direction of revised WHO classification of Tumors of haematopoietic and lymphoid tissues. Rinsho Ketsueki. 2009;50:1401–6.PubMed Tomonaga M. Outline and direction of revised WHO classification of Tumors of haematopoietic and lymphoid tissues. Rinsho Ketsueki. 2009;50:1401–6.PubMed
13.
Zurück zum Zitat Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–82.PubMedCrossRef Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–82.PubMedCrossRef
Metadaten
Titel
MicroRNA-146a rs2910164 polymorphism and the risk of diffuse large B cell lymphoma in the Chinese Han population
verfasst von
Haifeng Zhuang
Jianping Shen
Zhiyin Zheng
Xiusu Luo
Ruilan Gao
Xiaofen Zhuang
Publikationsdatum
01.12.2014
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 12/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0306-z

Weitere Artikel der Ausgabe 12/2014

Medical Oncology 12/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.